EmeraMed Ltd is a biotechnology firm developing the lipophilic, blood-brain-barrier passing metal chelator and antioxidant Irminix®


EmeraMed strives to bring cures for diseases faced by animals as well as humans. The Company received veterinary Minor Use for Minor Species (MUMS) designation for Irminix® in December 2012. This is similar to orphan designation for human drugs. The Swedish MPA has since approved compassionate-use treatments for predatory birds. The Company has successfully treated a paralyzed eagle and a dizzy and stumbling owl. Both birds were heavily intoxicated with mercury and after short periods of treatment were up and flying in the Swedish countryside again. The Company will continue to develop veterinary uses for Irminix® in the future.